United States Sen. Gary Peters has reintroduced bipartisan legislation to help prevent future infant formula shortages.

Abbott, a health care products conglomerate ... approved by the U.S. Food and Drug Administration (FDA). Yet unlike baby formula, the toddler milk products are not regulated by the FDA and are ...

There were unforgiveable shortcomings in management, which included critical information not reaching senior officials as ...

The lawsuit accuses Abbott of creating products called “transition formulas,” “follow-on formulas,” “weaning formulas” and “toddler milks” to boost earnings as infant formula sales ...

(Read the full complaint below.) Abbott loses $500 million baby formula verdict Why Abbott and Dexcom buried the hatchet in their glucose monitor patent fight Abbott tries to claw back $24.3 ...

A bipartisan effort in the U.S. Senate seeks to improve the safety of infant formula. Introduced by Sen. John Hoeven, R-ND, and Sen. Gary Peters, D-MI, ...

LANSING, Mich. — Sen. Gary Peters has reintroduced a bill designed to stop future infant formula shortages from happening. The bipartisan legislation was drafted after a nationwide shortage in 2022 ...

Abbott, a health care products conglomerate ... approved by the U.S. Food and Drug Administration (FDA). Yet unlike baby formula, the toddler milk products are not regulated by the FDA and are ...

The alarm certainly sounded long and loud in 2022 when Abbott recalled Similac, Alimentum, and EleCare powdered infant ...

Danielle and Andrew West spent their first month as parents praying their child would live. Their son Owen, born six weeks early in November 2015, developed necrotizing enterocolitis a few days ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money, recently emphasized the ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more ...